The investigation of different post-processing strategies of combination therapy on patients with chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12001921

Enrollment

Unknown

Registered

2012-02-05

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Continuing Combination Therapy:LAM+ADV or LDT+ADV combination therapy

Switching to Monotherapy:LAM or ADV or LDT monotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) compensated CHB who were suboptimal response to initial adefovir monotherapy but obtained undetectable HBV DNA after at least one year of lamivudine or telbivudine add-on therapy; (2) lack of co-infection with hepatitis C virus or human immunodeciency virus; (3) lack of other causes of liver disease, such as autoimmune hepatitis, and primary biliary cirrhosis; (4) no evidence of advanced liver diseases, such as decompensated cirrhosis, severe hepatitis, and hepatic carcinoma.

Exclusion criteria

Exclusion criteria: (1) have poor compliance; (2) no availability of detailed laboratory test results

Design outcomes

Primary

Measure	Time frame
Sustained Biochemical Response;Sustained Virological Response;Serological Response;	—

Secondary

Measure	Time frame
Safety;	—

Countries

China

Contacts

Public ContactHong Tang

htang6198@hotmail.com+86 18980601313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026